Switch theme
Sign up to access all valuation multiples
Kusuri No Aoki Holdings is a pharmaceutical retail chain that sells health, beauty, and cleaning supplies. The company operates stores that focus primarily on residential areas in Japan. Kusuri's business includes pharmaceutical drugs, and the company also operates a bone-marrow bank. The company breaks out its sales into four different product lines, including health, beauty, life, and dispensing. The vast majority of the company's revenue is derived from its life product category, followed by beauty products. Most of Kusuri's revenue is derived from the Hokuriku region.
1999
8.0K+
LTM Revenue $3.4B
LTM EBITDA $257M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kusuri No Aoki has a last 12-month revenue (LTM) of $3.4B and a last 12-month EBITDA of $257M.
In the most recent fiscal year, Kusuri No Aoki achieved revenue of $3.0B and an EBITDA of $220M.
Kusuri No Aoki expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kusuri No Aoki valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.4B | XXX | $3.0B | XXX | XXX | XXX |
| Gross Profit | $872M | XXX | $810M | XXX | XXX | XXX |
| Gross Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $257M | XXX | $220M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $174M | XXX | $127M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $123M | XXX | $84.5M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $281M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kusuri No Aoki's stock price is JPY 3535 (or $24).
Kusuri No Aoki has current market cap of JPY 358B (or $2.5B), and EV of JPY 395B (or $2.7B).
See Kusuri No Aoki trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $2.5B | XXX | XXX | XXX | XXX | $1.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kusuri No Aoki has market cap of $2.5B and EV of $2.7B.
Kusuri No Aoki's trades at 0.8x EV/Revenue multiple, and 11.2x EV/EBITDA.
Equity research analysts estimate Kusuri No Aoki's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kusuri No Aoki has a P/E ratio of 19.9x.
See valuation multiples for Kusuri No Aoki and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 10.5x | XXX | 11.2x | XXX | XXX | XXX |
| EV/EBIT | 15.6x | XXX | 17.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.9x | XXX | 23.0x | XXX | XXX | XXX |
| EV/FCF | -98.7x | XXX | 989.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKusuri No Aoki's last 12 month revenue growth is 10%
Kusuri No Aoki's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Kusuri No Aoki's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kusuri No Aoki's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kusuri No Aoki and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kusuri No Aoki acquired XXX companies to date.
Last acquisition by Kusuri No Aoki was XXXXXXXX, XXXXX XXXXX XXXXXX . Kusuri No Aoki acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kusuri No Aoki founded? | Kusuri No Aoki was founded in 1999. |
| Where is Kusuri No Aoki headquartered? | Kusuri No Aoki is headquartered in Japan. |
| How many employees does Kusuri No Aoki have? | As of today, Kusuri No Aoki has 8.0K+ employees. |
| Is Kusuri No Aoki publicy listed? | Yes, Kusuri No Aoki is a public company listed on TKS. |
| What is the stock symbol of Kusuri No Aoki? | Kusuri No Aoki trades under 3549 ticker. |
| When did Kusuri No Aoki go public? | Kusuri No Aoki went public in 2006. |
| Who are competitors of Kusuri No Aoki? | Similar companies to Kusuri No Aoki include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Kusuri No Aoki? | Kusuri No Aoki's current market cap is $2.5B |
| What is the current revenue of Kusuri No Aoki? | Kusuri No Aoki's last 12 months revenue is $3.4B. |
| What is the current revenue growth of Kusuri No Aoki? | Kusuri No Aoki revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Kusuri No Aoki? | Current revenue multiple of Kusuri No Aoki is 0.8x. |
| Is Kusuri No Aoki profitable? | Yes, Kusuri No Aoki is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kusuri No Aoki? | Kusuri No Aoki's last 12 months EBITDA is $257M. |
| What is Kusuri No Aoki's EBITDA margin? | Kusuri No Aoki's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Kusuri No Aoki? | Current EBITDA multiple of Kusuri No Aoki is 10.5x. |
| What is the current FCF of Kusuri No Aoki? | Kusuri No Aoki's last 12 months FCF is -$27.5M. |
| What is Kusuri No Aoki's FCF margin? | Kusuri No Aoki's last 12 months FCF margin is -1%. |
| What is the current EV/FCF multiple of Kusuri No Aoki? | Current FCF multiple of Kusuri No Aoki is -98.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
